MusclePharm Corporation (OTCMKTS:MSLP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
Submission of Matters to a Vote of Security Holders.
The 2018 Annual Meeting of Stockholders (the “Annual Meeting”) of MusclePharm Corporation (the “Company”) was held on December 7, 2018. A total of 10,305,700 shares of the Company’s common stock were present at the meeting in person or by proxy, which represented 67% of the shares entitled to vote, and which constituted a quorum for the transaction of business. The matters presented for a vote and the related results are as follows:
1.Election of Directors
Proposal one was the election of four nominees to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been elected and qualified, or until their earlier resignation, removal or death. The results of the vote were as follows:
|
Nominee |
||||
|
Ryan Drexler |
3,286,666 |
3,092,101 |
1,819 |
3,925,114 |
|
John J. Desmond |
3,324,486 |
3,036,412 |
19,688 |
3,925,114 |
|
William J. Bush |
3,324,477 |
3,036,421 |
19,688 |
3,925,114 |
|
Brian Casutto |
3,287,454 |
3,072,832 |
20,300 |
3,925,114 |
to the foregoing votes, the four nominees listed above were elected to serve on the Company’s Board of Directors for a term expiring at the 2019 annual meeting of stockholders. There were no additional director nominations brought before the Annual Meeting.
2.Ratification of the Independent Registered Public Accountants
Proposal two was the ratification of the appointment of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The results of the vote were as follows:
|
6,467,743 |
3,770,625 |
67,332 |
to the foregoing vote, the ratification of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2018 was approved.
3.Advisory, Non-Binding Vote on the Compensation of Named Executive Officers
Proposal three was the approval, on a non-binding, advisory basis, the compensation paid to the Company’s named executive officers as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on October 26, 2018. The results of the vote were as follows:
|
3,289,817 |
3,085,415 |
5,354 |
3,925,114 |
to the foregoing vote, on a non-binding, advisory basis, the compensation paid to the Company’s named executive officers, was approved.
About MusclePharm Corporation (OTCMKTS:MSLP)
MusclePharm Corporation is a performance lifestyle company. The Company develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. The Company’s portfolio of brands targets various types of fitness enthusiasts, including professional, combat sport, weight training, bodybuilding, running, basketball, soccer, cross fit, golf, tennis, volleyball and other active lifestyle activities. The MusclePharm Sport Series includes supplements that cover the needs of athletes, including their workout needs. MusclePharm Hybrid Series products include Assault, Amino1 and Combat Protein Powder. FitMiss products are designed and formulated for the active woman’s lifestyle utilizing ingredients that cover the range of busy women’s needs, including weight loss, multi-vitamins, protein shakes, detox, skin care and pre-workout energy mixes. MusclePharm Core products include BCAA 3:1:2, CLA Core and Fish Oil.
